Teva Pharmaceutical Industries has signed a definitive agreement to acquire Labrys Biologics, a development stage biotechnology company focused on treatments for chronic and episodic migraines.

Under the terms of the agreement, Labrys Biologics will receive an upfront payment of $200m from Teva and up to $625m in contingent payments upon achievement of certain pre-launch milestones.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Closing of the deal is subject to antitrust approval and satisfaction of other conditions.

"LBR-101 represents a much-needed option for the management of this truly debilitating condition."

As Teva aims to become a global leader in pain care by 2020, Labrys’s acquisition will add a significant migraine prophylaxis dimension to its extensive pain care franchise that currently includes a range of investigational, approved and marketed treatments for migraine, cancer pain and chronic pain.

Labrys is developing LBR-101, a humanised monoclonal antibody that binds to calcitonin gene-related peptide, a well-validated target in migraine. LBR-101 is currently in Phase IIb clinical trials for prevention of episodic and chronic migraines.

LBR-101 was originally discovered by Rinat Neuroscience (bought by Pfizer in 2006) and was acquired by Labrys from Pfizer in 2012.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

LBR-101 has completed five Phase I trials with 94 healthy volunteers dosed with active drug. A sixth Phase I bridging study tested intravenous and subcutaneous doses (24 participants received active medication).

The companies claim that potential peak sales for LBR-101 are estimated to reach $2bn-$3bn.

Teva chief scientific officer and global R&D president Michael Hayden said: "With its long half-life, target specificity and favorable pharmacokinetic profile allowing for infrequent, and convenient, subcutaneous administration, LBR-101 represents a very exciting biologic product candidate, and much-needed option, for the management of this truly debilitating condition."